Fresenius Kabi Reveals €800m Biopharma Ambitions By 2026
German Firm Also Raises Its Revenue, Margin Guidance For 2023
During a lengthy and comprehensive capital markets day, Fresenius Kabi spelled out its vision and plans for a return from the company’s burgeoning Biopharmaceuticals business, following years of major investment.
